Tumor organoids harboring KRAS, NRAS, BRAF, or PIK3CA hotspot mutations exhibited a relatively higher IC50 and area under the drug response curve (AUC) for cetuximab than organoids without hotspot mutations in these genes (Fig. 3E,F). This evidence concerns the gene BRAF and neoplasm.